Genocea Biosciences Inc. sell StockNews.com
Summary
This prediction was cancelled by the user.Genocea Biosciences (Symbol GNCA) (WKN A2PK76) is a publicly traded, clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel vaccines and immunotherapies for various infectious diseases and cancer. With a unique approach to unlocking the power of T-cells in rapid vaccine and immunotherapy discovery, the company has established a robust pipeline targeting a wide spectrum of viral, bacterial, and parasitic diseases as well as oncology indications. Notable programs include GEN-003 for genital herpes and GEN-009, an innovative and personalized neoantigen cancer vaccine. Listed on the Nasdaq stock exchange, Genocea is dedicated to improving patient outcomes through cutting-edge research, expertise in immune targeting, and a strong commitment to scientific innovation.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Genocea Biosciences Inc. | - | - | - |
| iShares Core DAX® | 4,64 % | 7,49 % | 6,99 % |
| iShares Nasdaq 100 | 4,47 % | 16,80 % | 40,28 % |
| iShares Nikkei 225® | 7,67 % | 16,86 % | 47,87 % |
| iShares S&P 500 | 2,47 % | 9,90 % | 28,43 % |
Comments by StockNews_com for this prediction
In the thread Genocea Biosciences Inc. diskutieren
In the thread Trading Genocea Biosciences Inc.